From March 4th to 5th, the 12th CBIC Cell Biology Industry Conference & 3rd International Conference on Cell Therapy and Regenerative Medicine was held in Chengdu. Co-organized by the Chengdu Health Commission, Sichuan Hospital Association, Chengdu High-tech Medical Association, and other units, the event attracted top scientists, medical institution representatives, and biopharmaceutical executives from around the globe. Attendees gathered to engage in in-depth exchanges on frontier areas such as innovative cell therapies, diversified cell industry applications, clinical translation of stem cells, and organoid clinical translation, jointly exploring the future direction of the industry.

At the conference, Chief Scientist Wang Jianxun served as a speaker for the session on innovative cell therapy applications, delivering a presentation titled "Research Progress of NK/CAR-NK Cell Therapy." Professor Wang began by detailing the advantages and challenges of NK cell and CAR-NK cell therapies. He pointed out that as core members of innate immunity, NK cells can kill tumor cells through direct lysis and cytokine secretion. CAR-NK cell therapy further endows NK cells with specific targeting capabilities through genetic engineering, significantly improving therapeutic specificity. Compared to CAR-T cell therapy, CAR-NK cell therapy boasts advantages such as superior efficacy in hematologic and solid tumors, universal applicability, high industrial capacity, lower costs, and reduced risk of side effects, indicating broad application prospects in the field of oncology.

Professor Wang Jianxun also shared Shenzhen Cell Valley's relevant products and core competitiveness in NK/CAR-NK cell therapy. For instance, the retroviral vectors prepared by Shenzhen Cell Valley achieve transduction efficiencies exceeding 70% with stable expression. The company has optimized culture processes to achieve ex vivo expansion folds of up to tens of thousands of times and enhances CAR-NK cell persistence by adding autocrine/membrane-bound IL-15. These technological breakthroughs effectively address limitations in the clinical translation of CAR-NK cells, such as low transduction efficiency, difficulties in production and proliferation, and poor persistence.

Professor Wang Jianxun stated that Shenzhen Cell Valley will continue to delve into the field of NK and CAR-NK cell therapy, constantly exploring new technologies and methods to provide safer and more effective cell therapy solutions for patients. Simultaneously, the company will strengthen cooperation with renowned domestic and international universities, medical institutions, and research organizations to jointly promote the rapid development of the cell and gene therapy industry.

This presentation not only showcased Shenzhen Cell Valley's latest research achievements and clinical progress in NK and CAR-NK cell therapy but also further enhanced the company's reputation and influence within the industry. In the future, Shenzhen Cell Valley will continue to uphold the development philosophy of "Innovation, Collaboration, and Win-Win," making greater contributions to the prosperity of the cell and gene therapy industry.